On September 12, 2022, Phantom Neuro, the first-of-its-kind neurotech startup that delivers a low power, high accuracy system for lifelike control of robotic orthopedic technologies, announced a $6 million funding round led by new investor Time BioVentures. The round included participation from another new investor, Risk & Return (R²), an innovative venture fund focused on "capitalism for good". Wilson Sonsini Goodrich & Rosati advised Time BioVentures on the transaction.

Phantom Neuro aims to dramatically enhance the lives of amputees and other patients with function deficits. The company's solution combines low-risk implantable sensors, AI, and enabling software to offer unparalleled control of orthopedic technologies, such as prosthetic limbs and exoskeletons.

The Wilson Sonsini team that advised lead investor Time BioVentures included Mark Solakian, Jake Gatof, Reilly Clark, and Aaron Gordon.

For more information, please see Phantom Neuro’s press release.